CD44V6、EGFR在卵巢上皮癌中的表达及临床意义

Clinical correlation of CD44V6 and EGFR expressions in ovarian epithelial carcinoma

目的：探讨ＣＤ４４Ｖ６及ＥＧＦＲ在卵巢上皮癌中的表达及临床意义。方法： 以 ＳＰ免疫组织化学方法检测 ３３５例卵巢上皮癌， １８例卵巢上皮瘤和 １５例正常卵巢组织石蜡标本 ＣＤ４４Ｖ６及 ＥＧＦＲ的表达，并分析卵巢上皮癌的临床病理资料。结果：①正常卵巢组织 ＣＤ４４Ｖ６及 ＥＧＦＲ均呈阴性表达，卵巢上皮瘤及上皮癌中均有中ＣＤ４４Ｖ６及ＥＧＦＲ表达，正常卵巢与卵巢良恶性肿瘤之间的表达差异有高度显著性（Ｐ＜０．０１），卵巢上皮癌与卵巢上皮瘤之间的表达差异无显著性（Ｐ＞０．０５）；（２）ＣＤ４４Ｖ６及ＥＧＦＲ的阳性表达与卵巢上皮癌的临床分期有关（Ｐ＜０．０５），与组织分化程度及病理类型无关（Ｐ＞０．０５）；③ＣＤ４４Ｖ６及ＥＧＦＲ的阳性表达与卵巢上皮癌预后有关（Ｐ＜０．０５）；④ＣＤ４４Ｖ６及ＥＧＦＲ在卵巢上皮癌中的表达差异无显著性（Ｐ＞０．０５），二者具有相关性（Ｐ＜０．０５）．结论：ＤＤ４４Ｖ６及ＥＧＦＲ可能是卵巢上皮癌发生的相关基因，与肿瘤的发展及转移有关。检测 ＣＤ４４Ｖ６及 ＥＧＦＲ可以估计卵巢上皮癌患者的预后，指导化疗。

Objective: To investigate correlation of CD44V6 and human epidermal growth factor receptor (EGFR) expression in ovarian epithelial carcinoma and explore its clinical significance. Methods: The expressions of CD44V6 and EGFR were examined in 35 ovarian epithelial carcinoma, 18 ovarian benign tumor and 15 normal ovarian tissues using SP immunohistochemistry. Results:(1)There were no expressions of CD44V6 and EGFR in normal controls, but overexpression in some ovarian epithelial tumor(2) CD44V6 and EGFR overexpression were correlated with the clinial stages of ovarian epithelial carcinoma(P<0.05), but were uncorrelated with histodifferentiation and pathological type(P>0.05)(3)CD44V6 were also correlated with prognosis of ovarian epithelial carcinoma (P<0.05).(4)In ovarian epithelial carcinoma, the overexpression of CD44V6 and EGFR was correlated well with EG- FR(P<0.015).Conclusions:CD44V6 and EGFR may be correlated with the occurrence, development and metastasis of ovarian epithelial carcinoma. The measurement of CD44V6 and EGFR can be used to evaluate the prognosis of ovarian epithelial carcinoma and to assist in chemotherapy.